In breast carcinomas, binding of extracellular Gal-9 to Tim-3 at the surface of DCs suppresses their production of CXCL9, resulting in a significantly decreased anti-tumour response, especially in the context of a treatment by paclitaxel (123). The gene discussed is HAVCR2; the disease is neoplasm.